However, use of 8AQ derivatives is limited by the risk of life-threatening acute haemolytic anemia (AHA) in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals. The gene discussed is G6PD; the disease is autoimmune hemolytic anemia.